^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    HER2 dimerization inhibitor

    Related drugs:
    Apply
    Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer (NRG-GY026) (NCT05256225)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/16/2022
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    HER-2 • TP53
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants with Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer) (NCT05415215)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/05/2022
    Primary completion :
    11/20/2024
    Completion :
    12/31/2025
    HER-2
    |
    HER-2 amplification • EGFR positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (NCT03387553)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/06/2018
    Primary completion :
    08/29/2026
    Completion :
    08/29/2026
    HER-2 • PGR • CD4
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122) (NCT05894239)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    07/28/2023
    Primary completion :
    09/28/2026
    Completion :
    12/28/2032
    HER-2 • PIK3CA
    |
    HER-2 positive • PIK3CA mutation
    |
    tamoxifen • fulvestrant • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV) (NCT05704829)
    Phase 2
    West German Study Group
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    02/05/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2028
    HER-2
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer (BOLD-1) (NCT02625441)
    Phase 3
    Helsinki University Central Hospital
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    12/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
    Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery (NCT06348134)
    Phase 2
    University of Chicago
    Not yet recruiting
    Last update posted :
    02/05/2025
    Initiation :
    01/01/2026
    Primary completion :
    07/01/2034
    Completion :
    07/01/2036
    HER-2
    |
    HER-2 positive
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • letrozole • goserelin acetate • Soltamox (tamoxifen citrate)
    Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (CHERRY-PICK) (NCT06068985)
    Phase 2
    Latin American Cooperative Oncology Group
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/05/2024
    Primary completion :
    10/01/2026
    Completion :
    10/01/2031
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) (NCT05296798)
    Phase 3
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    07/04/2022
    Primary completion :
    03/31/2027
    Completion :
    12/31/2030
    HER-2 • ER
    |
    ER positive • EGFR positive
    |
    paclitaxel • docetaxel • tamoxifen • Perjeta (pertuzumab) • giredestrant (GDC-9545) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease (NCT04588545)
    Phase 1/2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/10/2020
    Primary completion :
    07/29/2025
    Completion :
    07/29/2025
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (NCI-2016-00570) (NCT02827877)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/24/2025
    Initiation :
    07/15/2016
    Primary completion :
    07/02/2020
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 positive + HER-2 overexpression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Trazimera (trastuzumab-qyyp)
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery (SWOG S1613) (NCT03365882)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    11/27/2017
    Primary completion :
    11/01/2022
    Completion :
    11/30/2025
    HER-2 • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Perjeta (pertuzumab) • irinotecan • Trazimera (trastuzumab-qyyp)
    A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY) (NCT01358877)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    01/13/2025
    Initiation :
    11/08/2011
    Primary completion :
    12/19/2016
    Completion :
    11/28/2024
    HER-2 • ER • PGR
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • epirubicin • cyclophosphamide intravenous
    Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer (NCT03125928)
    Phase 2
    Fox Chase Cancer Center
    Active, not recruiting
    Last update posted :
    01/10/2025
    Initiation :
    06/13/2017
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab)
    Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients with Stage I-III HER2 Positive Breast Cancer (NCI-2020-00332) (NCT04249622)
    Phase 2
    Mayo Clinic
    Active, not recruiting
    Last update posted :
    12/31/2024
    Initiation :
    09/18/2020
    Primary completion :
    12/27/2022
    Completion :
    08/03/2025
    HER-2
    |
    HER-2 positive
    |
    Perjeta (pertuzumab)
    A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer (NCT04024462)
    Phase 3
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    12/20/2024
    Initiation :
    02/05/2020
    Primary completion :
    12/13/2021
    Completion :
    11/11/2025
    PIK3CA
    |
    HER-2 positive • HER-2 amplification • PIK3CA mutation • EGFR positive
    |
    Herceptin (trastuzumab) • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • cyclophosphamide intravenous
    Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (NCT06038539)
    Phase 3
    Biocon Biologics UK Ltd
    Not yet recruiting
    Last update posted :
    12/17/2024
    Initiation :
    01/31/2025
    Primary completion :
    03/15/2026
    Completion :
    11/15/2026
    HER-2 • ER • PGR
    |
    HER-2 overexpression • ER negative
    |
    carboplatin • docetaxel • Perjeta (pertuzumab)
    Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT03101748)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    12/13/2024
    Initiation :
    01/29/2018
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    HER-2
    |
    HER-2 positive • HER-2 negative • HER-2 negative + HR negative
    |
    Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar) • cyclophosphamide intravenous
    Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab (NCT02436993)
    Phase 2
    University of California, Irvine
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    04/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab)
    Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer (NCT05891561)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    11/27/2024
    Initiation :
    11/01/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol (NCT01817452)
    Phase 2
    West German Study Group
    Active, not recruiting
    Last update posted :
    11/13/2024
    Initiation :
    03/01/2014
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    HER-2 • ER • PGR
    |
    PGR negative
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
    A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050) (NCT03726879)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    11/05/2024
    Initiation :
    01/11/2019
    Primary completion :
    02/05/2021
    Completion :
    08/24/2023
    HER-2 • PD-L1 • ER • PGR
    |
    PD-L1 expression • HER-2 positive • ER negative
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • paclitaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous
    Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer (InTTercePT) (NCT05041842)
    Phase 2
    UNICANCER
    Active, not recruiting
    Last update posted :
    10/17/2024
    Initiation :
    12/17/2021
    Primary completion :
    04/30/2025
    Completion :
    04/30/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant • Tukysa (tucatinib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    MARGetuximab Or Trastuzumab (MARGOT) (NCT04425018)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    10/02/2024
    Initiation :
    07/13/2020
    Primary completion :
    09/05/2024
    Completion :
    07/01/2027
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Herzuma (trastuzumab-pkrb) • Margenza (margetuximab-cmkb) • Ogivri (trastuzumab-dkst)
    A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT) (NCT04569747)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    10/01/2024
    Initiation :
    01/11/2021
    Primary completion :
    09/01/2026
    Completion :
    09/01/2030
    HER-2 • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (NCT01796197)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/30/2024
    Initiation :
    08/01/2013
    Primary completion :
    06/01/2018
    Completion :
    11/01/2024
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • cyclophosphamide intravenous
    A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer (HELEN-006) (NCT04547907)
    Phase 3
    Henan Cancer Hospital
    Recruiting
    Last update posted :
    09/20/2024
    Initiation :
    09/18/2020
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HER-2
    |
    HER-2 expression
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • albumin-bound paclitaxel
    DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC (DAPHNE) (NCT03716180)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/12/2024
    Initiation :
    11/05/2018
    Primary completion :
    10/08/2020
    Completion :
    09/01/2030
    HER-2
    |
    HER-2 positive • HER-2 negative
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
    T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA (NCT02326974)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/07/2024
    Initiation :
    01/01/2015
    Primary completion :
    06/01/2018
    Completion :
    01/01/2028
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine)
    Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast (NCT03304080)
    Phase 1/2
    Icahn School of Medicine at Mount Sinai
    Active, not recruiting
    Last update posted :
    08/01/2024
    Initiation :
    12/20/2017
    Primary completion :
    07/31/2025
    Completion :
    12/31/2025
    HER-2 • PGR
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • anastrozole
    Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer (NCT04957212)
    Phase 3
    Cinnagen
    Completed
    Last update posted :
    07/26/2024
    Initiation :
    08/11/2018
    Primary completion :
    05/27/2020
    Completion :
    05/27/2020
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • P013 (pertuzumab biosimilar)
    A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) (NCT05283837)
    Phase 3
    Zydus Lifesciences Limited
    Completed
    Last update posted :
    07/18/2024
    Initiation :
    09/26/2022
    Primary completion :
    09/06/2023
    Completion :
    09/06/2023
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive
    |
    docetaxel • Perjeta (pertuzumab)
    Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC (NCT03417544)
    Phase 2
    Nancy Lin, MD
    Active, not recruiting
    Last update posted :
    07/04/2024
    Initiation :
    05/21/2018
    Primary completion :
    05/20/2020
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Perjeta (pertuzumab)
    Detect V / CHEVENDO (Chemo vs. Endo) (DETECT V) (NCT02344472)
    Phase 3
    Prof. Wolfgang Janni
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    09/01/2015
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    HER-2
    |
    HER-2 positive • HR positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • capecitabine • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • vinorelbine tartrate • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging (NCT02993198)
    Phase 2
    Northwestern University
    Active, not recruiting
    Last update posted :
    06/03/2024
    Initiation :
    04/01/2015
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2 • PGR
    |
    HER-2 overexpression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 (NCT05385705)
    Phase 1
    Vall d'Hebron Institute of Oncology
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    05/11/2022
    Primary completion :
    09/11/2026
    Completion :
    04/11/2027
    CD8 • CD4 • NCAM1 • CASP3
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • cyclophosphamide
    Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. (NCT04629846)
    Phase 3
    Qilu Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    04/19/2024
    Initiation :
    11/23/2020
    Primary completion :
    08/22/2022
    Completion :
    10/24/2023
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 amplification
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • QL1209 (pertuzumab biosimilar)
    Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (PH002-TP-II) (NCT03272477)
    Phase 2
    Palleos Healthcare GmbH
    Completed
    Last update posted :
    04/17/2024
    Initiation :
    10/05/2017
    Primary completion :
    07/14/2020
    Completion :
    03/04/2024
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • tamoxifen • Perjeta (pertuzumab) • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension • cyclophosphamide intravenous
    Testing a New Imaging Agent to Identify Cancer (NCT04692831)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    11/30/2020
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    HER-2
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Perjeta (pertuzumab)
    Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 (NCT01996267)
    Phase 3
    The Netherlands Cancer Institute
    Active, not recruiting
    Last update posted :
    03/29/2024
    Initiation :
    12/01/2013
    Primary completion :
    12/01/2018
    Completion :
    12/01/2030
    HER-2
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification
    |
    Herceptin (trastuzumab) • carboplatin • paclitaxel • 5-fluorouracil • Perjeta (pertuzumab) • cyclophosphamide • epirubicin